What you should know:
1. WuXi developed the biologics conjugation center in June 2018.
2. The expanded center will span 5.5 acres and will allow the company to commercially manufacture antibody-drug conjugate products.
4. WuXi is currently developing more than 20 antibody-drug conjugates.
More articles on biologics:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
